[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neurotrophic-keratopathy-stage-1\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neurotrophic-keratopathy-stage-1":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100631568",false,"NCT07502378","Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic Keratopathy Patients With Tear Deficiency","Inclusion Criteria:\n\n* Neurotrophic Keratopathy stage 1 diagnosis based on the following: Presence of 3+ fluorescein staining in central cornea and decreased corneal sensation (Cochet-Bonnet less than 4cm in the central cornea)\n* Baseline unanesthetized Schirmer's test ≤ 10 mm\n* Females of childbearing potential must have a negative pregnancy test.\n* Best corrected distance visual acuity (BCDVA), using corrective lenses, if necessary, in the study eye of at least +1.0 Log MAR (Snellen \\\u003C20\u002F200).\n\nExclusion Criteria:\n\n* Evidence of any active ocular infection or any intraocular inflammation.\n* Evidence of any persistent epithelial defect\u002Fulcer or any corneal scar\u002Fcorneal edema.\n* Presence of any other ocular conditions that require topical medications during the treatment phase.\n* History of severe systemic allergies or severe ocular allergies.\n* Inability to suspend topical medications 8 days prior to the starting date and artificial tears 2 hours prior to the first study visit and remain off for the duration of the study.\n* History of any ocular surgery within three months before study visit 1.\n* Ocular surgery expected during the duration of the study.\n* Use of refractive\u002Ftherapeutic contact lenses during the study period.\n* Female subjects who are pregnant\u002Fhave a positive pregnancy test result or are breastfeeding or intend to become pregnant during the study treatment period.\n* Drug addiction\u002Falcohol abuse.\n* Participation in another clinical trial concurrently","ALL","18 Years",{"count":17,"type":18},50,"ESTIMATED","INTERVENTIONAL",[21],"PHASE4","STUDY OBJECTIVE To assess if acoltremon 0.003% improves tear production in patients with Stage 1 Neurotrophic Keratopathy.",[24,25],"Ocular Surface Disease","Neurotrophic Keratopathy Stage 1",[24],"RECRUITING","2026-03-25",{"date":30,"type":31},"2026-03-31","ACTUAL",{"date":33,"type":18},"2026-03-27",{"date":35,"type":18},"2027-08-31",{"name":37,"class":38},"University of South Florida","OTHER",""]